These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 27398953

  • 1. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
    Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, Holtzman DM, Benzinger TL, Morris JC, Fagan AM.
    Ann Neurol; 2016 Sep; 80(3):379-87. PubMed ID: 27398953
    [Abstract] [Full Text] [Related]

  • 2. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM.
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [Abstract] [Full Text] [Related]

  • 3. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
    Babulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TLS, Fagan AM, Morris JC, Roe CM.
    Am J Geriatr Psychiatry; 2016 Nov; 24(11):1095-1104. PubMed ID: 27426238
    [Abstract] [Full Text] [Related]

  • 4. Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid.
    Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Jack CR, Alzheimer's Disease Neuroimaging Initiative.
    Alzheimers Dement; 2011 Mar; 7(2):133-41. PubMed ID: 21282074
    [Abstract] [Full Text] [Related]

  • 5. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 6. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
    Gomar JJ, Conejero-Goldberg C, Davies P, Goldberg TE, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2016 Oct; 51(4):1085-97. PubMed ID: 26967213
    [Abstract] [Full Text] [Related]

  • 7. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.
    Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC.
    Arch Neurol; 2009 Dec; 66(12):1557-62. PubMed ID: 20008664
    [Abstract] [Full Text] [Related]

  • 8. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
    Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, Kornhuber J, Morris JC, Fagan AM.
    J Alzheimers Dis; 2017 Dec; 55(2):813-822. PubMed ID: 27792012
    [Abstract] [Full Text] [Related]

  • 9. Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls.
    Mattsson N, Insel PS, Donohue M, Jagust W, Sperling R, Aisen P, Weiner MW, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Neurol; 2015 May; 72(5):554-60. PubMed ID: 25775167
    [Abstract] [Full Text] [Related]

  • 10. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.
    Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J, Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.
    JAMA Neurol; 2018 May 01; 75(5):608-619. PubMed ID: 29482212
    [Abstract] [Full Text] [Related]

  • 11. Pittsburgh compound B-negative dementia: a possibility of misdiagnosis of patients with non-alzheimer disease-type dementia as having AD.
    Shimada H, Ataka S, Takeuchi J, Mori H, Wada Y, Watanabe Y, Miki T.
    J Geriatr Psychiatry Neurol; 2011 Sep 01; 24(3):123-6. PubMed ID: 21750305
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder.
    Ances BM, Benzinger TL, Christensen JJ, Thomas J, Venkat R, Teshome M, Aldea P, Fagan AM, Holtzman DM, Morris JC, Clifford DB.
    Arch Neurol; 2012 Jan 01; 69(1):72-7. PubMed ID: 22232345
    [Abstract] [Full Text] [Related]

  • 14. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.
    Zwan M, van Harten A, Ossenkoppele R, Bouwman F, Teunissen C, Adriaanse S, Lammertsma A, Scheltens P, van Berckel B, van der Flier W.
    J Alzheimers Dis; 2014 Jan 01; 41(3):801-7. PubMed ID: 24705549
    [Abstract] [Full Text] [Related]

  • 15. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
    Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM.
    Ann Neurol; 2006 Mar 01; 59(3):512-9. PubMed ID: 16372280
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
    Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, Benzinger TL.
    JAMA Neurol; 2016 Oct 01; 73(10):1192-1200. PubMed ID: 27548756
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.
    Grimmer T, Riemenschneider M, Förstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T, Wester HJ, Kurz A, Drzezga A.
    Biol Psychiatry; 2009 Jun 01; 65(11):927-34. PubMed ID: 19268916
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R, D'Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman DM.
    JAMA Neurol; 2016 May 01; 73(5):561-71. PubMed ID: 27018940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.